The whole-genome landscape of medulloblastoma subtypes
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The overlap observed between the G3 and G4 tumors with respect to MYC amplification supports the working hypothesis that these medulloblastomas are not easily separable in part because they originate from a shared cerebellar progenitor cell pool, with each group arising from arrest at different points along a developmental stage continuum (8, 23).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methylation array–based classification studies have categorized the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4; and the G3/G4-7 and G3/G4-8 subgroups as primarily G4 (8).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“T 0) 42 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“The relatively recent recognition of consensus MB subgroups has rapidly changed the way MB is studied in the research setting and how it is diagnosed and treated in the clinic 39 .”
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“The functional effect of the mutations was annotated using Annovar 43 and the variants were assessed for their confidence and split into somatic and non-somatic calls.”
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Cited by
Items 701–800 of 998
Ampudia-Mesias, E., Cameron, C. S., Yoo, E., Kelly, M. D., Anderson, S. M., Manning, R., Abrahante, J. E., Moertel, C. L., Yim, H., Odde, D. J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084416 · Cited by 5
“MYCN and GLI2 copy number aberrations are characteristic of this subgroup [10,11].”
BackgroundMethodInfluentialAlmousa, A., Erjan, A., Sarhan, N., Obeidat, M., Alshorbaji, A., Amarin, R., Alawabdeh, T., Abu-Hijlih, R. A., Mujlli, M., Ibrahimi, A. K., et al. (2024) · Cancers · doi:10.3390/cancers16213609 · Cited by 4
“The two subgroups, Group 3 and Group 4 medulloblastomas, collectively known as non-WNT/non-SHH, lack specific subgroup-defining mutations but exhibit distinct clinical and biological features [25].”
BackgroundThe transcription factor LHX2 mediates and enhances oncogenic BMP signaling in medulloblastoma
Ohata, Y., Ali, M. M., Tsubakihara, Y., Itoh, Y., Rosén, G., Bergström, T., Morén, A., Cancela, I. G., Nakada, A., Voytyuk, O., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01488-6 · Cited by 5
“Integration of all RNA-seq datasets identi fi ed LHX2 , among the 28 DEGs, shared between spatial and cellular analyses; LHX2 expression was stimulated by BMP7, inhibited by LDN193189 treatment and enriched in the pSMAD1/5-high MB tumor cells (Fig.”
Huang, H., Yu, C., Yang, Y., Chang, Y., Jou, S., Lin, K., Lu, M., Chang, H., Chou, S., Ni, Y., et al. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29569 · Cited by 4
Mitochondrial DNA mutations in Medulloblastoma
Funke, V. L. E., Sandmann, S., Melcher, V., Seggewiß, J., Horvath, J. E., Jäger, N., Kool, M., Jones, D., Pfister, S. M., Milde, T., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01602-0 · Cited by 4
Self-citationTreatment of Medulloblastoma in the Adolescent and Young Adult Population: A Systematic Review
Otth, M., Weiser, A., Lee, S.-Y., von Rohr, L. R., Heesen, P., Stücklin, A. G., & Scheinemann, K. (2024) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2024.0044 · Cited by 6
“5,7,10,72 This highlights that even when tumors share molecular features, underlying additional genetic aspects are different between children and adults; for example, there is a much more frequent occurrence of TERT promotor mutation in adult SHH medulloblastoma.”
Lira-Díaz, E., Cruz-Márquez, R., González-Pedroza, M. G., González-Pérez, Ó., Morales‐Luckie, R. A., & Acevedo‐Fernández, J. J. (2024) · Journal of Nanotechnology · doi:10.1155/2024/2263514 · Cited by 6
Wen, W., Zhao, S., Jiang, Y., Ou, C., Guo, C., Jia, Z., Li, J., Huang, Y., Xu, H., Pu, P., et al. (2024) · Genetics in Medicine Open · doi:10.1016/j.gimo.2024.101899 · Cited by 4
“Moreover, the prevalent SBS3 signature in our BRCA1/2 -negative patients reinforced the hypothesis of its independence from germline BRCA1/2 P variants 69,70 and emphasized the role of HRD in MBC development again.”
The pivotal role of autophagy in the pathogenesis and therapy of medulloblastoma
Richard, S. A. (2024) · Future Oncology · doi:10.1080/14796694.2024.2420629 · Cited by 4
Nanopore sequencing as a cutting-edge technology for medulloblastoma classification
Filser, M., Torrejon-Diaz, J., Merchadou, K., Dufour, C., Girard, E., Bourneix, C., Lemaître, E., Gharsalli, T., Brillet, R., Wong, J., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae279 · Cited by 8
Freire, N. H., Herlinger, A. L., Vanini, J., Dalmolin, M., Fernandes, M. A. C., Nör, C., Ramaswamy, V., de Farias, C. B., Brunetto, A. T., Brunetto, A. L., et al. (2025) · Cells · doi:10.3390/cells14020072 · Cited by 4
“In the D283 neurospheres, VPA also increased the TP53 levels (20-fold, p 0.01) (Figure 4B) Moreover, the ChIP-qPCR results indicated that TP53 may be epigenetically modulated by VPA in the D283 neurospheres (Figure 4C).”
InfluentialSelf-citationFan, J. J., Erickson, A. W., Carrillo-García, J., Wang, X., Skowron, P., Wang, X., Chen, X., Shan, G., Dou, W., Bahrampour, S., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.01.001 · Cited by 5
Self-citationTran, Q. T., Jia, S., Alom, M. Z., Wang, L., Mullighan, C. G., Tatevossian, R., & Orr, B. A. (2025) · Brain Pathology · doi:10.1111/bpa.70000 · Cited by 4
“DNA methylation patterns from whole-genome bisulfite sequencing (WGBS) show high fidelity with array-based patterns [13, 14].”
Frassanito, P., Thomale, U. W., Obersnel, M., Romano, A., Leblond, P., Knerlich‐Lukoschus, F., Due‐Tønnessen, B. J., Thompson, D. N. P., Rocco, F. D., & the CPN Lyon 2024 Consensus Conference Group (2025) · Child s Nervous System · doi:10.1007/s00381-025-06799-0 · Cited by 6
“Paradoxically, the molecular landscape of medulloblastoma is now well established [78]; however, targeted therapies have been investigated only in the very restricted subgroup of SHH-medulloblastomas.”
Chromatin modification abnormalities by CHD7 and KMT2C loss promote medulloblastoma progression
Wang, W.-C., Kumegawa, K., Chapman, O. S., Shiraishi, R., Xiao, Z., Okonechnikov, K., Sun, Y., Pfister, S. M., Feng, W., Uesaka, N., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115673 · Cited by 4
Self-citationMedulloblastoma: Molecular Targets and Innovative Theranostic Approaches
Foti, A., Allia, F., Briglia, M., Malaguarnera, R., Tamburrini, G., Cecconi, F., Pagliarini, V., Nazio, F., & Graziano, A. C. E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060736 · Cited by 7
“Currently, the driver oncogenes and/or tumor suppressor genes linked to this alteration remain unidentified, since there is not a single gene mutated in >10% of cases [27].”
Long-range chromatin interactions in pathogenic gene expression control
Kong, N., & Jung, I. (2020) · Transcription · doi:10.1080/21541264.2020.1843958 · Cited by 4
Uchida, E., Sasaki, A., Shirahata, M., Suzuki, T., Adachi, J.-I., Mishima, K., Yasuda, M., Fujimaki, T., Ichimura, K., & Nishikawa, R. (2022) · Brain Tumor Pathology · doi:10.1007/s10014-021-00421-2 · Cited by 4
A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies
Rozowsky, J. S., Meesters, J. I., Lammers, J. A. S., Belle, M. L., Nierkens, S., Kranendonk, M. E. G., Kester, L. A., Calkoen, F., & van der Lugt, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864423 · Cited by 5
“Groups of samples identified through these approaches can be clinically relevant, as transcriptomes have been shown to correspond to anatomical location [for pilocytic astrocytomas (79, 80)], diagnosis subgroups [for medulloblastoma (81)], oncogenic drivers [H3K27 mutation status for pediatric high-grade gliomas (82)]…”
BackgroundMontemagno, C., Luciano, F., & Pagès, G. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2217-9_1 · Cited by 5
Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression
Wynn, D. T., Rodríguez‐Blanco, J., Long, J., Yang, F., Shen, C., Fei, D. L., Tang, H., Hanson, D. J., & Robbins, D. J. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac144 · Cited by 5
Simultaneous Nbs1 and p53 inactivation in neural progenitors triggers high‐grade gliomas
Reuß, D., Downing, S. M., Camacho, C. V., Wang, Y., Piro, R. M., Herold‐Mende, C. C., Wang, Z., Hofmann, T. G., Sahm, F., von Deimling, A., et al. (2023) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12915 · Cited by 6
Self-citationLinked-read based analysis of the medulloblastoma genome
Zwaig, M., Johnston, M. J. G., Lee, J. J. Y., Farooq, H., Gallo, M., Jabado, N., Taylor, M. D., & Ragoussis, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1221611 · Cited by 4
Self-citationFirst report of medulloblastoma in a patient with MUTYH ‐associated polyposis
Villy, M., Warcoin, M., Filser, M., Buecher, B., Golmard, L., Suybeng, V., Schwartz, M., Bièche, I., Vacher, S., Laurence, V., et al. (2023) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12929 · Cited by 4
“and Helgager et al.(16,17) A role of MUTYH deficiency in this poor prognosis cannot be ruled out.”
BackgroundInfluentialCancer Models in Xenopus tropicalis by CRISPR/Cas9 Mediated Knockout of Tumor Suppressors
Naert, T., & Vleminckx, K. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8784-9_11 · Cited by 4
SHH medulloblastoma in a young adult with a TCF4 germline pathogenic variation
Blanluet, M., Masliah‐Planchon, J., Giurgea, I., Bielle, F., Girard, E., Andrianteranagna, M. J. D. D., Clémenceau, S., Bourneix, C., Bürglen, L., Doummar, D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01983-4 · Cited by 4
Lack of KBTBD4 Mutations in Molecularly Classified Brazilian Medulloblastomas
Leal, L. F., Cavagna, R. D. O., Campanella, N. C., Mançano, B. M., de Almeida, G. C., Matsushita, M. D. M., Junior, C. R. D. A., Saggioro, F. P., Stávale, J. N., Malheiros, S. M. F., et al. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz066 · Cited by 4
Invited Review: The role and contribution of transcriptional enhancers in brain cancer
Arabzade, A., Stuckert, A. J., Bertrand, K. C., & Mack, S. C. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12612 · Cited by 4
Nasir, A., Cardall, A., Othman, R. T., Nicolaou, N., Lourdusamy, A., Linke, F., Onion, D., Ryzhova, M. V., Cameron, H., Valente, C., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab030 · Cited by 8
Self-citationPetroni, M., Fabretti, F., Giulio, S. D., di Robilant, V. N., Monica, V. L., Moretti, M., Belardinilli, F., Bufalieri, F., Coppa, A., Paci, P., et al. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12837 · Cited by 3
Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor
Bae, J., Won, J., & Park, S. (2018) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2018.0057 · Cited by 5
Flow Cytometry Approaches to Obtain Medulloblastoma Stem Cells from Bulk Cultures
Kumar, P., & Garg, N. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1952-0_8 · Cited by 4
WNT: an unexpected tumor suppressor in medulloblastoma
Manoranjan, B., Adile, A., Venugopal, C., & Singh, S. K. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2020.1834903 · Cited by 5
Systematic silencing of oncogenic fusion transcripts with ultra-precise CRISPR-Cas13bPreprint
Hu, W., Chen, H., Casan, J. M. L., Shembrey, C., He, S., Brown, L. M., Hughes, T. P., White, D. L., de Weck, A., Voskoboinik, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.10.637348 · Cited by 4
Collins, R. R. J., Gee, R. R. F., Tozandehjani, S., Bayat, T., Sanchez, M. C. H., Gutierrez, J. S. S., Breznik, B., Lee, A. K., Peters, S., Connelly, J. P., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02055-3 · Cited by 4
“Germline mutations in the WNT inhibitor APC or somatic mutations in CTNNB1 are found in almost all WNT-MBs [39, 55].”
Skull–meninges–brain connectivity and extra-axial brain tumours
Islim, A. I., Vyziotis, A., Pathmanaban, O. N., Coope, D. J., King, A. T., Brough, D., Jardine, L., Couper, K. N., & Greenhalgh, A. D. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf311 · Cited by 4
“78 In mouse models of SHH medulloblastoma, Lyve1 + meningeal macrophages were found to have a tumour suppressive function via secretion of CXCL4, and their depletion led to tumour growth.”
Karaulic, A., Fournier, C., & Pagès, G. (2025) · Cancers · doi:10.3390/cancers17223659 · Cited by 4
Strategies for the Molecular Classification of Medulloblastoma
Ramírez‐Chiquito, J. C., & Juárez‐Méndez, S. (2025) · Biomedicines · doi:10.3390/biomedicines13122845 · Cited by 4
“%) are not identified to designate either of these two molecular groups [14,30–34].”
Medulloblastoma stem cell programs: Molecular roadmaps of disease progression
Zagozewski, J. L., Haldipur, P., Millen, K. J., & Werbowetski‐Ogilvie, T. E. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.10.018 · Cited by 3
Singh, A. K., Cheng, D., Haltom, A. R., Yang, Y., Dobson, T., Hatcher, R. J., Rajaram, V., & Gopalakrishnan, V. (2025) · Oncogene · doi:10.1038/s41388-025-03651-2 · Cited by 3
Versatile roles of inositol hexakisphosphate in the ubiquitin-proteasome system
Rusnac, D.-V., Zheng, N., & Xie, X. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253032 · Cited by 4
“As a substrate receptor of CRL3, KBTBD4 (Kelch repeat and BTB domain-containing protein 4) acquires neomorphic substrate-binding activity through cancer-associated indel mutations identified in medulloblastoma [55].”
Seltene Tumordispositionssyndrome mit Manifestation im Kindesalter
Ripperger, T., Wimmer, K., & Kratz, C. P. (2017) · Medizinische Genetik · doi:10.1007/s11825-017-0150-6 · Cited by 3
Gajjar, A. J. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28645 · Cited by 3
Self-citationNiesen, J., Hermans‐Borgmeyer, I., Krüger, C., Schoof, M., Modemann, F., & Schüller, U. (2023) · iScience · doi:10.1016/j.isci.2023.107501 · Cited by 3
“In a cohort of SHH-MB patients, GLI2 and MYCN amplifications also occurred simultaneously.(6,9,12) On the other hand, in SHH/TP53 MB patients (generally children, 4–17 years), amplification ofGLI2,MYCN, or SHH arises, while mutations in SUFU and SMO are rare or absent.”
Barateiro, L. G. R. P., Cavagna, R. D. O., dos Reis, M. B., de Paula, F. E., Teixeira, G. R., Moreno, D. A., Bonatelli, M., Santana, I. V. V., Saggioro, F. P., Neder, L., et al. (2024) · Neuropathology · doi:10.1111/neup.12979 · Cited by 3
“In the cBioPortal database, which includes mainly patients from Europe or North America, 16,24 – 27 the reported frequencies are: TP53 (3.9%, 25/645); PIK3CA (2.2%, 14/645); and KIT (0%, 0/645).”
InfluentialWang, S., Xie, D., Yue, H., Li, G., Jiang, B., Gao, Y., Zheng, Z., Zheng, X., & Wu, G. (2025) · Biomedicines · doi:10.3390/biomedicines13020304 · Cited by 4
“To predict tumor responses to immunotherapy, we employed the TIDE and subclass mapping models [30], with TIDE assessing immune evasion and subclass mapping gauging responses across different tumor subtypes.”
Self-citationDepani, S., Vasiljevic, A., Mynarek, M., Dufour, C., Pfaff, E., Maaz, A. U. R., Guerrini‐Rousseau, L., Doz, F., Hasselblatt, M., Ajithkumar, T., et al. (2025) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2025.100217 · Cited by 3
Self-citationMolecular glue unexpectedly mimics the effect of cancer mutations
Bushman, J. W., & Potts, P. R. (2025) · Nature · doi:10.1038/d41586-025-00090-7 · Cited by 3
Li, Y., Chen, L., Xue, S., Song, Z., Liu, H., Li, H., Shen, W., Zhang, C., & Wu, H. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01512-9 · Cited by 4
“Mutational patterns associated with SHH-subgroup medullo-blastoma include loss-of-function mutations or deletions in PTCH1 or SUFU , activating mutations in SMO , and ampli fi cations of GLI1/2 and MYCN [21, 26].”
Monnikhof, M., Schakelaar, M. Y., Meulenbroeks, C., Quist, M., Perzolli, A., Selten, A., Koster, C., Maassen, D. S. C., Canelo, A. M., Fredriks, M., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf099 · Cited by 11
Self-citationRole of the U1 snRNP Complex in Human Health and Disease
Soares, E. S., Leal, C. B. Q. D. S., Sinatti, V. V. C., Bottos, R. M., & Zimmer, C. G. M. (2025) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.70026 · Cited by 5
“In medulloblastoma, U1 snRNP dysfunction disrupts important developmental signaling pathways, such as Wnt and SHH, which are critical for both tumor initiation and progression (Northcott et al. 2017).”
Médulloblastome. Anatomie pathologique
Siegfried, A., & Delisle, M. (2018) · Neurochirurgie · doi:10.1016/j.neuchi.2017.12.006 · Cited by 6
SUFU: The Jekyll and Hyde of the Cerebellum
Kim, L. J. Y., Bhargava, S., Gimple, R. C., & Rich, J. N. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.01.013 · Cited by 3
Molecular progression of SHH-activated medulloblastomas
Korshunov, A., Okonechnikov, K., Sahm, F., Ryzhova, M. V., Stichel, D., Sievers, P., Meyer, J., Schrimpf, D., Zheludkova, O., Голанов, А. В., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02022-y · Cited by 4
Self-citationPaik, S., Maule, F., & Gallo, M. (2020) · Genome · doi:10.1139/gen-2020-0097 · Cited by 5
Identification of hub genes correlated with sleep deprivation using co-expression analysis
Xu, H., Lin, S.-Z., Shi, K., Qiu, J.-J., Hu, J., Yu, Z., Dai, D., Zhang, N., Liang, M., Cai, H.-D., et al. (2021) · Sleep And Breathing · doi:10.1007/s11325-021-02321-3 · Cited by 3
Self-citationNK cells in brain tumors: From biology to treatment
Fares, J., Gupta, S. K., Gopalakrishnan, V., & Khatua, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00021-7 · Cited by 3
Pediatric Brain Tumors: From Modern Classification System to Current Principles of Management
Ozair, A., Khan, E. I., Bhat, V., Faruqi, A., & Nanda, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100442 · Cited by 7
Clinical Prognostic Implications of Wnt Hub Genes Expression in Medulloblastoma
Martins-da-Silva, A., Baroni, M., Salomão, K. B., Chagas, P. S., Bonfim-Silva, R., Geron, L., Cruzeiro, G. A. V., Silva, W. A., Corrêa, C. A. P., Carlotti, C. G., et al. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01217-4 · Cited by 4
Stemness Correlates Inversely with MHC Class I Expression in Pediatric Small Round Blue Cell Tumors
Müller, L., Kschischo, M., Vokuhl, C., Stahl, D. J., & Gütgemann, I. (2022) · Cancers · doi:10.3390/cancers14153584 · Cited by 3
“The four principal molecular subgroups of medulloblastoma WNT, SHH, Group 3, and Group 4 are based on distinct transcriptional and epigenetic signatures defining clinically relevant patient subsets [26].”
BackgroundIn vivofunctional characterization of EGFR variants identifies novel drivers of glioblastoma
Yu, K., Kong, K., Lozzi, B., Luna-Figueroa, E., Cervantes, A., Curry, R. N., Mohila, C., Rao, G., Jalali, A., Mills, G. B., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac215 · Cited by 4
Williamson, D., Schwalbe, E. C., Bailey, S., & Clifford, S. C. (2023) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12903 · Cited by 2
“subtype VIII) require time to accrue more mutations or that the mutations required are—by virtue of the mode of mutation—inherently less likely to occur [4].”
BackgroundDang, D. D., Rosenblum, J. S., Shah, A. H., Zhuang, Z., & Doucet-O’Hare, T. T. (2023) · Cancers · doi:10.3390/cancers15092511 · Cited by 4
“A tumour registry initiative”
Nair, R. P., Nayal, B., Beedkar, S., & Menon, G. R. (2023) · World Neurosurgery X · doi:10.1016/j.wnsx.2023.100227 · Cited by 3
Insights into the molecular roles of FOXR2 in the pathology of primary pediatric brain tumors
Gharbaran, R. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104188 · Cited by 3
The Pathology according to p53 Pathway
Hatano, Y. (2023) · Pathobiology · doi:10.1159/000535203 · Cited by 3
“…(4% [7]), dedifferentiated liposarcoma (4% [7]), breast fi broepithelial tumor (4% [61]), adenoid cystic carcinoma (5% [62]), medulloblastoma (5% [63]), chronic lymphocytic leukemia (5% [64]), EBV-positive stomach and esophageal cancer (7% [7]), cervical squamous carcinoma (7% [7]), invasive…”
BackgroundCola, A. D., Foss, A., Gilbertson, R. J., & Pathania, M. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-034650 · Cited by 3
HYENA detects oncogenes activated by distal enhancers in cancer
Yu, A., Yesilkanal, A. E., Thakur, A., Wang, F., Yang, Y., Phillips, W., Wu, X., Muir, A., He, X., Spitz, F., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae646 · Cited by 2
Self-citationInterrogating molecular data for medulloblastoma risk stratification
Ferretti, E., & Pò, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30585-0 · Cited by 3
Germline microsatellite genotypes differentiate children with medulloblastoma
Rivero-Hinojosa, S., Kinney, N. A., Garner, H. R., & Rood, B. R. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz179 · Cited by 3
Embryonal Tumors of the Central Nervous System: The WHO 2016 Classification and New Insights
Pinheiro, J., Almeida, J. C., & Lopes, J. M. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001923 · Cited by 3
Role of liquid biopsy in central nervous system tumors
Chakraborty, R., Suri, V. S., Dandapath, I., Singh, J., Sharma, M., & Sarkar, C. (2021) · International Journal of Neurooncology · doi:10.4103/ijno.ijno_425_21 · Cited by 3
Tumors of the Central Nervous System
Vega, J. E. V., Ballester, L. Y., & Schniederjan, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-73227-1_6 · Cited by 3
Splicing-Disrupting Mutations in Inherited Predisposition to Solid Pediatric Cancer
Alba‐Pavón, P., Alaña, L., Astigarraga, I., & Villate, O. (2022) · Cancers · doi:10.3390/cancers14235967 · Cited by 4
“For WNT-activated MB, Turcot Syndrome (APC) is the most common predisposition syndrome [56], a rare disorder characterized by the association of colonic polyposis and primary brain tumors [69].”
BackgroundEvolving paradigms for new agent development in pediatric oncology
Franson, A. T., & Fox, E. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000563 · Cited by 3
Precision oncogenomics in pediatrics: a personal reflectionPreprint
Campbell, C., & Greenfield, J. P. (2018) · Molecular Case Studies · doi:10.1101/mcs.a002865 · Cited by 3
Single-base precision design of CRISPR-Cas13b enables systematic silencing of oncogenic fusionsPreprint
Hu, W., Kumar, A., Qi, S., Sadras, T., Casan, J. M. L., Ma, D. K. G., Brown, L. M., Haber, M., Voskoboinik, I., Trapani, J. A., et al. (2022) · Research Square · doi:10.1101/2022.06.22.497105 · Cited by 2
PyOncoPrint: a python package for plotting OncoPrints
Park, J., & Paramasivam, N. (2023) · Genomics & Informatics · doi:10.5808/gi.22079 · Cited by 3
“OncoPrint, the plot to visualize an overview of the genetic variants of the deposited data at cBioPortal [1,2], has become popular, especially in the field of cancer genomics [3-7].”
BackgroundSelf-citationRadiation Therapy for Medulloblastoma
Harris, D., Yancey, J., Jones, G. P., Smith, K. S., Kessel, S. K., Laurie, F., Iandoli, M., Bishop‐Jodoin, M., Geng, Y., Ding, L., et al. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1005604 · Cited by 3
Systematic review and meta-analysis of bulk RNAseq studies in human Alzheimer’s disease brain tissuePreprint
Heberle, B. A., Fox, K. L., Libermann, L. L., Xavier, S. R. M., Dallarosa, G. T., Santos, R. C., Fardo, D. W., Viola, T. W., & Ebbert, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.07.622520 · Cited by 3
Lack of evidence for the transitional cerebellar progenitor
Smith, K. S., Li, Y., Haldipur, P., Gudenas, B. L., Millen, K. J., Hovestadt, V., & Northcott, P. A. (2025) · Nature · doi:10.1038/s41586-025-09247-w · Cited by 7
“Analysing this same data-set, and an additional published dataset 11 , showed that HNRNPH1 is not differentially expressed in group 3 compared with other subgroups after multiple testing correction and data normalization, neither of which were performed in the publication 10,11 (Fig.”
Self-citationA preliminary study on the mechanism of VASH2 in childhood medulloblastoma
Liu, W., Fu, Y., Wang, M., Zhao, J., Chen, J., Wang, Y., & Qin, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-42869-6 · Cited by 3
“In addition, the current gold standard for molecular typing of medulloblastoma mainly relies on DNA methylation assay 49 , but this method is expensive and has special requirements for the preservation and transportation of tumor tissues, therefore, in this study, we adopted a cost-effective…”
MethodMochizuki, A. Y., Nagaraj, C. B., Depoorter, D., Schieffer, K. M., & Kim, S. Y. (2024) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.63788 · Cited by 2
“While uncommon, in-frame insertions and deletions are described in SHH medulloblastoma (Northcott et al., 2017; Skowron et al., 2021), including a similar duplication (c.3130_3131insTGTGCG: p. Ala1044delinsValCysAla) within exon 18 (Skowron et al., 2021).”
MiR-326: Role and significance in brain cancers
Spinello, Z., Besharat, Z. M., Mainiero, F., Rughetti, A., Masuelli, L., Ferretti, E., & Catanzaro, G. (2025) · Non-coding RNA Research · doi:10.1016/j.ncrna.2025.02.006 · Cited by 2
Extracranial Metastatic Medulloblastoma: Two Case Reports and Systematic Literature Review
Moreno, D. A. V., Navarro-Fernández, J. O., Soto, G. R., Serrano-Murillo, M., & López-Valdés, J. C. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-01853-z · Cited by 2
“The new World Health Organization (WHO) 2021 classification divides medulloblastomas into four groups, with group 4 being the most common, up to 35% [6].”
Medulloblastoma’s master regulators and their association with patients’ risk
Michaelsen, G. L., Monteiro, T. D. S., Imparato, D. O., da Costa, J. V. A., Silva, D. R., de Souza, I. D., Ribeiro-Dantas, M. D. C., Cabral-Marques, O., Sinigaglia, M., & Dalmolin, R. J. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-00763-3 · Cited by 6
Evaluating the ‘ARID’ landscape of SWI/SNF complexes with relevance to cancer
Hore, P., Sarkar, S., & Bashyam, M. D. (2025) · Gene · doi:10.1016/j.gene.2025.149664 · Cited by 4
Coelho, K. M. D. P. A., Dalmolin, M., Pedack, F. R., Pickler, J. G. J., Barbosa, C., Recalde, J., Blasius, R., Silva, B. L., Fernandes, M. A. C., Fronza, H., et al. (2025) · Child s Nervous System · doi:10.1007/s00381-025-06913-2 · Cited by 3
Late Effects in Survivors of Pediatric Medulloblastoma: A Comprehensive Review
Izurieta‐Pacheco, A. C., Ramaswamy, V., Tsang, D. S., Rutka, J. T., Wasserman, J. D., Guger, S., Weidman, D. R., Nathan, P. C., Scheinemann, K., & Bennett, J. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.32132 · Cited by 3
Self-citationRuggiero, A., Gessi, M., d’Amati, A., Albanese, A., & Attinà, G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48030297 · Cited by 3
Williams, J. S., Farmer, D. M., Li, Q., Friske, J. D., Grenet, J. A., Robinson, S., Mercer, K., Goel, V., Janke, L. J., He, L., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea4966 · Cited by 5
Self-citationRichardson, S., Hicks, D., Gough, M., Butler, E. R., Thompson, D., Castle, J., Crosier, S., García-Ariza, M., Martín‐Guerrero, I., Plasschaert, S. L. A., et al. (2026) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(26)00067-2 · Cited by 5
Self-citationNovel PHOX2B germline mutation in childhood medulloblastoma: a case report
Ke, C., Shi, X., Chen, A. M., Li, C., Jiang, B., Huang, K., Zheng, Z., Liu, Y., Chen, Z., Luo, Y., et al. (2021) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-021-00170-5 · Cited by 2
“One genetic study showed that KBTBD4 and PRDM6 are candidate driver mutations in medulloblastoma [2].”
BackgroundSelf-citationZhu, W. (2022) · Scientific Programming · doi:10.1155/2022/9153885 · Cited by 2
“Based on physical knowledge, it is know that sound needs to use a medium to be transmitted to the eardrum and be perceived by humans [8].”
BackgroundMedulloblastoma and the DNA Damage Response
McSwain, L., Parwani, K. K., Shahab, S., Hambardzumyan, D., MacDonald, T. J., Spangle, J. M., & Kenney, A. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903830 · Cited by 4
“Additionally, the BRCA1/2 mutation status across MB patients remains unclear, though RNAseq data have shown upregulation of gene signatures associated with BRCA1/2 mutation in Group3 and 4 and a subset of SHH patients (45).”
BackgroundSkitchenko, R. K., Dinikina, Y. V., Smirnov, S., Krapivin, M., Smirnova, А. Y., Morgacheva, D. A., & Artomov, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1085947 · Cited by 3
“It was previously known that ARID2 coimmunoprecipitates with a-tubulin and that ARID2 localizes to the spindle pole during mitosis (59).”
BackgroundInfluentialNunes, S. R., Faria, C. C., Pimentel, J., Roque, R., Alaiz, H., Salazar, I., Pereira, T., Ferreira, F., & Roque, L. (2023) · Case Reports in Oncology · doi:10.1159/000527564 · Cited by 2
Neuroimaging of Brain Tumors in the Era of Radiogenomics
Batchala, P. P., Muttikkal, T. J. E., Donahue, J., Lopes, M. B. S., Williams, E. S., Tustison, N. J., & Patel, S. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_54 · Cited by 2
Wang, Y., Huang, J., Yin, X. H., Xu, Q., Sun, Y., Yao, Y., & Xiong, J. (2024) · Acta Neurochirurgica · doi:10.1007/s00701-024-05922-5 · Cited by 3
“Among these genes, EPHA7 (WNT), TBR1 (Group 4), and OTX2 (Group 3 and Group 4) were found to be associated with subgroup-specific somatic variants [14].”
Survival-Related Genes on Chromosomes 6 and 17 in Medulloblastoma
Vriend, J. P., & Liu, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147506 · Cited by 3
“It shows that SRGs”
BackgroundMethodInfluential
Metadata
- Authors
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
- Affiliations
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Hospital for Sick Children (CA)
- University of Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- European Molecular Biology Laboratory (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Broad Institute (US)
- Burdenko Neurosurgery Institute (RU)
- Oregon Health & Science University (US)
- Boston Children's Hospital (US)
- Universitätsklinikum Tübingen (DE)
- University Children's Hospital Tübingen (DE)
- University of California, Los Angeles (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Duke University (US)
- McGill University (CA)
- Kitasato University Hospital (JP)
- BC Cancer Agency (CA)
- University Hospital Heidelberg (DE)
- Corresponding author
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- ORCID
- Northcott, Paul A.
- Buchhalter, Ivo
- Morrissy, A. Sorana
- Hovestadt, Volker
- Weischenfeldt, Joachim
- Zichner, Thomas
- Rudneva, Vasilisa A.
- Warnatz, Hans-Jörg
- Sidiropoulos, Nikos
- Phillips, Aaron H.
- Schumacher, Steven
- Kleinheinz, Kortine
- Waszak, Sebastian M.
- Erkek, Serap
- Jones, David T. W.
- Kool, Marcel
- Zapatka, Marc
- Jäger, Natalie
- Hutter, Barbara
- Bieg, Matthias
- Paramasivam, Nagarajan
- Gu, Zuguang
- Ishaque, Naveed
- Imbusch, Charles D.
- Hübschmann, Daniel
- Amstislavskiy, Vyacheslav
- Robinson, Giles W.
- Zhou, Xin
- Wu, Gang
- Finkelstein, David
- Liu, Yanling
- Cavalli, Florence M. G.
- Ramaswamy, Vijay
- Wu, Xiaochong
- Ryzhova, Marina
- Cho, Yoon-Jae
- Pomeroy, Scott L.
- Schuhmann, Martin
- Ebinger, Martin
- Liau, Linda M.
- Mora, Jaume
- McLendon, Roger E.
- Jabado, Nada
- Kumabe, Toshihiro
- Moore, Richard A.
- Mungall, Andrew J.
- Wong, Tina
- Jones, Steven J. M.
- Witt, Olaf
- Milde, Till
- Capper, David
- Korshunov, Andrey
- Yaspo, Marie-Laure
- Kriwacki, Richard
- Gajjar, Amar
- Zhang, Jinghui
- Beroukhim, Rameen
- Fraenkel, Ernest
- Korbel, Jan O.
- Brors, Benedikt
- Schlesner, Matthias
- Eils, Roland
- Marra, Marco A.
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- Venue
- Nature
- Published
- 2017-07
- Volume
- 547
- Issue
- 7663
- Pages
- 311-317
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5905700
- OpenAlex
- W2737542366
- Cited by
- 1,112
- References
- 66
- Citations by year
- 2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
- FWCI
- 54.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- Nature (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Max Planck Digital Library (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Alexander and Margaret Stewart Trust
- Pediatric Brain Tumor Foundation (R01CA159859)
- Deutsches Krebsforschungszentrum
- Genome Canada (R01CA159859)
- Children's Hospital Foundation
- Ontario Institute for Cancer Research
- American Lebanese Syrian Associated Charities
- Government of Ontario
- Genome British Columbia (R01CA159859)
- Canada Research Chairs
- Brain Tumour Charity (GN-000356)
- Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
- Terry Fox Research Institute (R01CA159859)
- Deutsche Krebshilfe (109252)
- Hospital for Sick Children
- Stichting Kinderen Kankervrij
- BC Cancer Foundation (FDN-143288)
- Brain Tumour Research
- National Institutes of Health
- Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
- Garron Family Cancer Centre
- National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.